Manufacturer Recall of Potassium Chloride Extended-Release Capsules
Recently, Glenmark Pharmaceuticals recalled 114 batches of 750 mg. potassium chloride extended-release capsules USP 10 mEq because of dissolution failure. The failed dissolution of these capsules can result in high potassium levels, a condition called hyperkalemia. This can lead to a patient’s cardiac arrest. Normal potassium levels are essential to your body; potassium assists with the functioning of kidneys, heart, muscles, nerves, and cells. If you were harmed by any of the recalled potassium chloride extended release capsules, consult the seasoned Chicago-based dangerous drug attorneys of Moll Law Group about your legal options.
Give Our Lawyers A Call
As a patient, you may need to take potassium chloride extended release capsules orally, especially if you have an underlying medical condition that changes how potassium is excreted. Such underlying conditions include heart failure, renal dysfunction or hypertension. Each of these make it reasonably probable that you would develop hyperkalemia and cause severe adverse events. While it’s possible you might be asymptomatic, there is a chance you would suffer serious muscle weakness, cardiac arrhythmia, or even death.
The recalled capsules had been distributed around the country to wholesalers, distributors, and retail stores in 100-count and 500-count bottles. The manufacturer hasn’t yet gotten reports of hyperkalemia, or a serious adverse event related to the capsules. are packaged in 100-count (NDC 68462-357-01) and 500-count (NDC 68462-357-05) bottles.